Amit Aggarwal, PhDExecutive Director Translational Bioinformatics, Precision Medicine
Daiichi Sankyo
live WEBINAR
Multimodal Foundation Models in Action: Applications across Drug Development
Tempus and Daiichi Sankyo discuss the potential of novel multimodal AI, and its applications across drug development, from translational research to biomarker strategy and clinical deployment
Thursday, October 15th
10 AM PT / 12 PM CT / 1 PM ET
REGISTER NOW
All registrants will be sent the webinar recording shortly following the completion of the session.
what you’ll learn
Every stage of drug development — from target selection to post-launch adoption — runs on decisions made with incomplete information. Which targets and patients are most likely to respond? Where is there the greatest unmet need? Which trial design strategy will maximize the chance of hitting an endpoint? How can we increase adoption of biomarker testing in clinical practice? Pharma teams have historically had to answer these questions stage by stage, with fragmented data, small cohorts, and tools that don't talk to each other.
Join leaders from Tempus and Daiichi Sankyo for a conversation on how specialized, multimodal foundation models are creating a single AI backbone that spans the entire drug development and commercialization lifecycle — from predicting treatment benefit and payload sensitivity, to gaining insights on patient biology across modalities, to predicting trial scenarios and closing testing gaps after approval. This session will cover:
This session will cover:
- How specialized, multimodal foundation models — trained on deep, longitudinal, real-world data — uncover insights general-purpose AI models can't
- Novel, emerging applications of multimodal foundation models across the drug development lifecycle
- What it takes to bring these tools from proof-of-concept to the clinic — validation, regulatory engagement, and choosing the right deployment partner
SPEAKERS
READ BIO
Amit Aggarwal, PhD, is a translational bioinformatics and precision oncology leader with more than 20 years of experience applying cancer genomics, biomarker science, and real-world clinico-genomic data to oncology drug discovery and development.
He is Executive Director of Translational Bioinformatics at Daiichi Sankyo, where he has built and scaled bioinformatics capabilities supporting ADC programs, clinical biomarker strategy, and multimodal translational analytics. Previously, he served as Head of Oncology Genomics and Bioinformatics at Eli Lilly, contributing to target, biomarker and mechanistic insights, and patient tailoring strategies across discovery, translational, and clinical programs.
Razik YousfiSVP & GM, AI Products
READ BIO
Razik Yousfi is the SVP and GM of AI Products at Tempus, where he leads multi-modal Foundation Model initiatives and the development of AI products for Life Sciences and clinical care. He previously served as CEO and CTO of Paige AI, a pioneer in AI for computational pathology, through its acquisition by Tempus in 2025.
Razik is recognized for bridging deep technical expertise with executive leadership to deliver high-impact, AI-enabled solutions. A proponent of lean product development, he specializes in building and motivating cross-functional teams to solve complex problems. He is driven by a passion for creating customer-centric products at the intersection of data and AI—ultimately advancing a new generation of precision medicine tests that improve patient outcomes.
Caitlin McWilliamsVP, Strategy & Operations
READ BIO
Caitlin McWilliams serves as VP, Strategy and Operations for AI Products at Tempus, where she drives product strategy for multi-modal Foundation Model and digital biomarker initiatives. She collaborates with Life Science partners to connect Tempus’ AI capabilities to high value applications across the drug development lifecycle and to define, develop, and deliver novel AI products that de-risk drug development, commercialization, and positively impact patient care.
DH LeeSenior Director, Machine Learning
READ BIO
DH (Donghun) Lee is an experienced AI product leader who currently serves as Senior Director of Machine Learning at Tempus. Leading the AI team for the AI Products group, he focuses on driving multi-modal AI and life sciences R&D to develop AI-powered precision medicine applications for clinical impact.
